144 related articles for article (PubMed ID: 30319127)
61. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
62. [Docetaxel for octogerian metastatic castration-resistant prostate cancer patient: A multicentric ten years' experience].
Chanal E; Bousarsar A; Vallard A; Méry B; Vincent L; Flechon A; Chanelière AF; Daguenet E; Bouleftour W; Vassal C; Magné N; Guillot A
Bull Cancer; 2020 Feb; 107(2):171-180. PubMed ID: 31901292
[TBL] [Abstract][Full Text] [Related]
63. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
64. Cabazitaxel for the treatment of castration-resistant prostate cancer.
Agarwal N; Sonpavde G; Sartor O
Future Oncol; 2011 Jan; 7(1):15-24. PubMed ID: 21174534
[TBL] [Abstract][Full Text] [Related]
65. Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
Sun Y; Zou Q; Sun Z; Li C; Du C; Chen Z; Shan Y; Huang Y; Jin J; Ye ZQ; Xie L; Lin G; Feng Y; De Porre P; Liu W; Ye D
Int J Urol; 2016 May; 23(5):404-11. PubMed ID: 26879374
[TBL] [Abstract][Full Text] [Related]
66. [Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Lheureux S; Joly F
Bull Cancer; 2012 Sep; 99(9):875-80. PubMed ID: 22877855
[TBL] [Abstract][Full Text] [Related]
67. Safety and efficacy of maintenance therapy with a nonspecific cytochrome P17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer.
Gil-Bazo I; Arévalo E; Castillo A; Zudaire ME; Carranza OE; Fusco JP; Castañón E; Collado-Gómez V; López I; Gil-Aldea I
Clin Genitourin Cancer; 2013 Jun; 11(2):78-84. PubMed ID: 23260990
[TBL] [Abstract][Full Text] [Related]
68. [Role of chemotherapy in the treatment of castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2016 Jan; 74(1):143-8. PubMed ID: 26793895
[TBL] [Abstract][Full Text] [Related]
69. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
70. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
71. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy.
Yao A; Sejima T; Iwamoto H; Masago T; Morizane S; Honda M; Takenaka A
Int J Urol; 2015 Sep; 22(9):827-33. PubMed ID: 26087772
[TBL] [Abstract][Full Text] [Related]
72. Interstitial pneumonitis in a castration-resistant prostate cancer patient receiving cabazitaxel after thoracic radiation therapy: a case report.
Yanai Y; Kosaka T; Hongo H; Oya M
BMC Cancer; 2019 Jul; 19(1):720. PubMed ID: 31331293
[TBL] [Abstract][Full Text] [Related]
73. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer.
Thiery-Vuillemin A; Fizazi K; Sartor O; Oudard S; Bury D; Thangavelu K; Ozatilgan A; Poole EM; Eisenberger M; de Bono J
ESMO Open; 2021 Apr; 6(2):100089. PubMed ID: 33740734
[TBL] [Abstract][Full Text] [Related]
74. The role of taxane-based chemotherapy in the treatment of prostate cancer.
Huebner NA; Shariat SF; Resch I; Gust K; Kramer G
Curr Opin Urol; 2020 Jul; 30(4):527-533. PubMed ID: 32453003
[TBL] [Abstract][Full Text] [Related]
75. Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
Colloca G; Venturino A; Checcaglini F
Med Oncol; 2012 Jun; 29(2):776-85. PubMed ID: 21336988
[TBL] [Abstract][Full Text] [Related]
76. Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation.
Varnai R; Koskinen LM; Mäntylä LE; Szabo I; FitzGerald LM; Sipeky C
Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31398933
[TBL] [Abstract][Full Text] [Related]
77. Prostate cancer: Cabazitaxel-a key therapeutic option in prostate cancer.
Jayaram A; Attard G
Nat Rev Urol; 2015 Jun; 12(6):312-3. PubMed ID: 26032550
[No Abstract] [Full Text] [Related]
78. Key Notes on Pembrolizumab and Docetaxel Combination Therapy for Metastatic Castration-Resistant Prostate Cancer.
Thoman ME; Salari K
Eur Urol; 2022 Jul; 82(1):31-33. PubMed ID: 35396162
[No Abstract] [Full Text] [Related]
79. Overcoming chemotherapy resistance in prostate cancer.
Madan RA; Pal SK; Sartor O; Dahut WL
Clin Cancer Res; 2011 Jun; 17(12):3892-902. PubMed ID: 21680545
[TBL] [Abstract][Full Text] [Related]
80. Association between the anticancer efficacy of cabazitaxel and toll-like receptor 4 mediating signaling pathways in metastatic castration-resistant prostate cancer cells.
Guney Eskiler G; Ozkan AD; Eryilmaz IE; Egeli U; Cecener G
Hum Exp Toxicol; 2021 Jul; 40(7):1122-1129. PubMed ID: 33380212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
